Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (May 2024)
10 slides from Adalta's investor presentation, May 1, 2024
Slide 1: New growth enabling institutional investment
For personal use only New growth enabling institutional investment AdAlta Limited (ASX:1AD) A modern targeting system for next generation drugs Board discussion 1 May 2024
Slide 2: AdAlta's core strategies each have opportunities for growth
AdAlta’s core strategies each have opportunities for growth Current status For personal use only Partnering discussions advancing for: 1. Realise the value of lead asset AD-214 v Out-licensing; or v Co-development/asset financing v 3 active i-CAR-T discovery programs (Carina Biotech) 2. Progress i-C
Slide 3: AD-214 development plan
AD-214 development plan Phase I extension study • AD-214 well tolerated at target Phase II dose; PK/PD as predictied, consistent across doses; no evidence of negative ADA effects • Results comprehensively address pharma company clinical questions received to date Phase II financing strategy Product
Slide 4: AdCella: Connecting Asia innovation, Australian ecosystem and i-body technology
AdCella: Connecting Asia innovation, Australian ecosystem and i-body technology to deliver next generation cellular immunotherapies For personal use only World class advanced therapies clinical trial and translational research Experienced GMP manufacturing Geographic, time zone and and supply chain
Slide 5: AdCella business model
AdCella business model For personal use only 1. In-license market leading assets from Asia 3. Establish global manufacturing network and on-license to commercialization partners AdCella 2. Build value by establishing western regulated manufacturing, obtaining first western regulated clinical data 5
Slide 6: New investment provides access to up to $3.7 million additional funds
New investment provides access to up to $3.7 million additional funds New Life Sciences Capital LLC (NLSC) Meurs Group A US-based healthcare focused fund AdAlta’s second largest (and one of its longest standing) shareholders For personal use only A$ million First Investment Second Investment Third I
Slide 7: Benefits of new investment
Benefits of new investment Certainty For personal use only • Can progress growth initiatives independently of availability of funds from ongoing partnering initiatives for AD-214 Funds support growth initiatives § Accelerate progress of cellular immunotherapy collaboration with Flexibility SYNthesis
Slide 8: Other investment terms
Other investment terms Key investment terms – NLSC investment For personal use only § AdAlta to issue Placement Shares worth 109% of the 1st and 2nd investment amounts (100% of the 3rd investment) • Placement Shares to be issued over up to 36 months, if requested by NLSC § Purchase Price: $0.06 for
Slide 9: AdAlta's foundations in place for growth
AdAlta’s foundations in place for growth Lead asset AD-214 heading to Phase II (US$4.3b IPF market plus other indications), substantially de- risked by Phase I extension study clinical readouts For personal use only AD-214 partnering window open with multiple options in play: active market with comp
Slide 10: A modern targeting system for next generation drugs
A modern targeting system for next generation drugs For personal use only AdAlta Ltd (ASX:1AD) Investor Presentation October 2023 For more information please contact: Tim Oldham CEO & Managing Director +61 403 446 665 [email protected] Investor Relations The Capital Network Russell Katz +61 2 8